细胞因子风暴药物从 CAR-T 疗法转移到 COVID-19。
Cytokine Storm Drugs Move from CAR T to COVID-19.
出版信息
Cancer Discov. 2020 Jul;10(7):OF8. doi: 10.1158/2159-8290.CD-ND2020-008. Epub 2020 May 5.
Abstract
Early reports suggest that tocilizumab, an IL6 receptor-blocking antibody used to manage toxicities associated with chimeric antigen receptor T-cell therapy, may help control cytokine storms in people infected with COVID-19. Preliminary data from randomized trials are less clear-cut.
摘要
早期报告表明，托珠单抗（一种用于治疗嵌合抗原受体 T 细胞疗法相关毒性的白细胞介素 6 受体阻断抗体）可能有助于控制 COVID-19 感染者的细胞因子风暴。随机试验的初步数据则不那么明确。
Zotero 插件